SCHEMBL830022

SCHEMBL830022

CC(C)CCC(C)Oc1nc(-c2ccc(Cl)cc2)cc(C(F)(F)F)c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
CTRC Q99895 3/20 0.39
ACHE P22303 1/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
LTB4R Q15722 1/20 0.37
DHODH Q02127 2/20 0.36
ANO1 Q5XXA6 1/20 0.36
PLA2G1B P04054 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
PSD A5PKW4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL832712 0.90 MAPT (0.41) POLBMAPTALDH1A1L3MBTL1RXFP1
SCHEMBL831291 0.87 POLB (0.43) POLBMAPTALDH1A1L3MBTL1RXFP1
SCHEMBL829557 0.84 XDH (0.45) POLBMAPTALDH1A1L3MBTL1RXFP1
SCHEMBL831295 0.81 L3MBTL1 (0.41) POLBMAPTALDH1A1L3MBTL1RXFP1
SCHEMBL832584 0.81 ALDH1A1 (0.50) POLBMAPTALDH1A1L3MBTL1RXFP1
SCHEMBL830805 0.78 POLB (0.46) POLBMAPTALDH1A1L3MBTL1RXFP1
SCHEMBL829804 0.78 POLB (0.45) POLBMAPTALDH1A1L3MBTL1RXFP1
SCHEMBL831844 0.77 ALDH1A1 (0.42) MAPTALDH1A1L3MBTL1HPGDMEN1
SCHEMBL832846 0.77 MAPT (0.43) POLBMAPTALDH1A1L3MBTL1RXFP1
SCHEMBL832659 0.77 FABP3 (0.46) POLBMAPTALDH1A1L3MBTL1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT POLB 3352/4885MAPT 906/4885ALDH1A1 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.